1. Home
  2. SPT vs TMDX Comparison

SPT vs TMDX Comparison

Compare SPT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$11.10

Market Cap

633.9M

Sector

Technology

ML Signal

HOLD

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$124.15

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPT
TMDX
Founded
2010
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
633.9M
3.9B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
SPT
TMDX
Price
$11.10
$124.15
Analyst Decision
Buy
Buy
Analyst Count
10
8
Target Price
$26.00
$144.25
AVG Volume (30 Days)
1.0M
724.8K
Earning Date
11-05-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
170.70
EPS
N/A
2.54
Revenue
$443,750,000.00
$566,354,000.00
Revenue This Year
$13.30
$38.81
Revenue Next Year
$11.37
$20.49
P/E Ratio
N/A
$48.97
Revenue Growth
13.09
41.20
52 Week Low
$9.16
$55.00
52 Week High
$35.18
$156.00

Technical Indicators

Market Signals
Indicator
SPT
TMDX
Relative Strength Index (RSI) 54.23 43.84
Support Level $10.98 $120.82
Resistance Level $12.06 $133.29
Average True Range (ATR) 0.45 5.52
MACD 0.04 -0.91
Stochastic Oscillator 40.84 19.55

Price Performance

Historical Comparison
SPT
TMDX

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: